Related Experiment Video
Updated: Sep 3, 2025
05:39
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
1.9K
Describing IgA Myeloma: An Immunophenotypic and Molecular Approach
Yamac Akgun1, Yigit Baykara2, Sean M Hacking3
1Department of Pathology and Laboratory Medicine, University of Miami and Jackson Health System, Miami, Florida.
Rhode Island Medical Journal (2013)
|July 26, 2022
Summary
IgA-type multiple myeloma (IgA-MM) is aggressive. Lower CD56 expression in IgA-MM may drive its aggressive nature and extramedullary spread, impacting patient outcomes.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Plasma cell myeloma (PCM) is a clonal plasma cell disorder.
- IgA-type multiple myeloma (IgA-MM) exhibits aggressive behavior, increased morbidity, and mortality.
- The underlying biology of IgA-MM's aggressiveness remains unclear.
Purpose of the Study:
- To characterize the clinical, phenotypic, and cytogenetic features of IgA-MM.
- To investigate the role of CD56 expression in IgA-MM aggressiveness.
- To identify risk stratification in IgA-MM patients.
Main Methods:
- Flow cytometry for plasma cell phenotyping.
- Fluorescent in situ hybridization (iFISH) for cytogenetic analysis.
- Analysis of clinical, phenotypic, and cytogenetic data from IgA-MM patients.
Main Results:
- 68.1% of IgA-MM cases were intermediate or high risk.
- CD56 expression was less frequent in IgA-MM (52.8%) compared to other PCM subtypes.
- Lower CD56 expression may correlate with aggressive disease and extramedullary presentation.
Conclusions:
- IgA-MM exhibits distinct phenotypic and cytogenetic characteristics.
- Reduced CD56 expression is a potential biomarker for IgA-MM aggressiveness.
- Loss of CD56 may contribute to extramedullary disease in IgA-MM.
